200 related articles for article (PubMed ID: 17381379)
21. [Tendency and prospect of the development of new ARBs].
Kim S
Nihon Rinsho; 2002 Oct; 60(10):1881-6. PubMed ID: 12397678
[TBL] [Abstract][Full Text] [Related]
22. Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice.
Li L; Zhou N; Gong H; Wu J; Lin L; Komuro I; Ge J; Zou Y
Hypertens Res; 2010 Dec; 33(12):1289-97. PubMed ID: 20944638
[TBL] [Abstract][Full Text] [Related]
23. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
Suzuki H; Kanno Y; Sugahara S; Ikeda N; Shoda J; Takenaka T; Inoue T; Araki R
Am J Kidney Dis; 2008 Sep; 52(3):501-6. PubMed ID: 18653268
[TBL] [Abstract][Full Text] [Related]
24. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.
Demers C; McMurray JJ; Swedberg K; Pfeffer MA; Granger CB; Olofsson B; McKelvie RS; Ostergren J; Michelson EL; Johansson PA; Wang D; Yusuf S;
JAMA; 2005 Oct; 294(14):1794-8. PubMed ID: 16219883
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy-safety relationship of AT1 angiotensin II receptor antagonists: current data].
Paoletti V; Di Veroli C; Pugliese M; Cammarella I; Cavina G; Turchetti P; Mammarella A
Clin Ter; 2002; 153(1):61-4. PubMed ID: 11963637
[TBL] [Abstract][Full Text] [Related]
26. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
[TBL] [Abstract][Full Text] [Related]
27. Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.
Ram CV; Ramaswamy K; Qian C; Biskupiak J; Ryan A; Quah R; Russo PA
J Clin Hypertens (Greenwich); 2011 Nov; 13(11):801-12. PubMed ID: 22051424
[TBL] [Abstract][Full Text] [Related]
28. HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure--lessons learnt from a decade of trials.
McMurray JJ; Swedberg K
Eur J Heart Fail; 2010 Feb; 12(2):99-103. PubMed ID: 20083618
[No Abstract] [Full Text] [Related]
29. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.
Grosso AM; Bodalia PN; Macallister RJ; Hingorani AD; Moon JC; Scott MA
Int J Clin Pract; 2011 Mar; 65(3):253-63. PubMed ID: 21284790
[TBL] [Abstract][Full Text] [Related]
30. Maintaining goal blood pressures after switching from olmesartan to other angiotensin receptor blockers.
Saseen JJ; Ghushchyan V; Kaila S; Allen RR; Nair KV
J Clin Hypertens (Greenwich); 2013 Dec; 15(12):888-92. PubMed ID: 24102728
[TBL] [Abstract][Full Text] [Related]
31. Valsartan in chronic heart failure.
Ripley TL
Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480
[TBL] [Abstract][Full Text] [Related]
32. Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.
Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
Circ Cardiovasc Qual Outcomes; 2017 Oct; 10(10):. PubMed ID: 28974512
[TBL] [Abstract][Full Text] [Related]
33. Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study.
Eworuke E; Shinde M; Hou L; Paterson MJ; Jensen PB; Maro JC; Rai A; Scarnecchia D; Pennap D; Woronow D; Ghosh RE; Welburn S; Pottegard A; Platt RW; Lee H; Bradley MC
BMJ Open; 2023 Apr; 13(4):e070985. PubMed ID: 37068898
[TBL] [Abstract][Full Text] [Related]
34. Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?
McMurray JJ
Nat Clin Pract Cardiovasc Med; 2005 Mar; 2(3):128-9. PubMed ID: 16265452
[No Abstract] [Full Text] [Related]
35. Reduction of proteinuria with angiotensin receptor blockers.
Galle J
Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S36-43. PubMed ID: 18580865
[TBL] [Abstract][Full Text] [Related]
36. Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients.
Yoo YG; Lim MJ; Kim JS; Jeong HE; Ko H; Shin JY
Medicine (Baltimore); 2023 Nov; 102(46):e36098. PubMed ID: 37986329
[TBL] [Abstract][Full Text] [Related]
37. JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease.
Mochizuki S; Shimizu M; Taniguchi I; Kanae K; Yoshida S; Tajima N; Dahlöf B;
Cardiovasc Drugs Ther; 2004 Jul; 18(4):305-9. PubMed ID: 15367828
[TBL] [Abstract][Full Text] [Related]
38. Can angiotensin II receptor blockers be used in patients who have developed a cough or angioedema as a result of taking an ACE inhibitor?
Vidt DG
Cleve Clin J Med; 2001 Mar; 68(3):189-90. PubMed ID: 11263845
[No Abstract] [Full Text] [Related]
39. AT1-receptor blockers.
Petkun W
Eur Heart J; 2000 Feb; 21(4):335-7. PubMed ID: 10653684
[No Abstract] [Full Text] [Related]
40. A meta-analysis of randomized trials of telmisartan vs. valsartan therapy for blood pressure reduction.
Takagi H; Niwa M; Mizuno Y; Goto SN; Umemoto T;
Hypertens Res; 2013 Jul; 36(7):627-33. PubMed ID: 23344134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
